Physician profile
Corey E Ennis
NPI 1912392192
$2,466.07
in general payments reported to CMS, 2019-2025
25 companies · $799 in 2025
The $799 reported for 2025 was more than what 79% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $162 · 2023: $860 · 2024: $645 · 2025: $799.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,304.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,304.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $797.84 | 2022-2025 | |
| Novo Nordisk INC | $479.85 | 2023-2025 | Wegovy, Rybelsus, Ozempic |
| Amgen INC. | $165.80 | 2022-2025 | Otezla, Repatha, Otezla |
| Pfizer INC. | $155.09 | 2023-2025 | |
| Otsuka America Pharmaceutical, INC. | $103.44 | 2023-2025 | Rexulti |
| Sanofi Pasteur INC. | $90.79 | 2022-2025 | |
| Exact Sciences Corporation | $76.11 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Lundbeck LLC | $62.47 | 2025 | Rexulti |
| Corium, LLC | $59.93 | 2023 | Azstarys |
| Merck Sharp & Dohme LLC | $59.88 | 2022-2025 | Capvaxive, Gardasil 9 |
| Glaxosmithkline, LLC. | $52.56 | 2023-2025 | Shingrix, Bexsero, Trelegy Ellipta |
| Astellas Pharma US INC | $42.50 | 2023-2024 | Veozah |
| Takeda Pharmaceuticals U.S.A., INC. | $39.73 | 2022-2023 | Trintellix |
| Lilly USA, LLC | $37.41 | 2022-2024 | Mounjaro |
| Vertex Pharmaceuticals Incorporated | $29.82 | 2025 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exeltis, USA INC. | $29.20 | 2025 | Slynd |
| Alexion Pharmaceuticals, INC. | $26.07 | 2024 | Ultomiris |
| Seqirus USA INC | $23.56 | 2023 | Fluad Quadrivalent, Flucelvax Quadrivalent |
| Alnylam Pharmaceuticals INC. | $22.84 | 2025 | Givlaari |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $20.96 | 2025 | Xifaxan |
| Sobi, INC | $20.87 | 2023 | |
| Novartis Pharmaceuticals Corporation | $20.74 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.04 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $15.48 | 2025 | Airsupra |
| Renalytix Ai, INC. | $15.09 | 2023 | Kidneyintelx Blood Collection Convenience Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Corey Ennis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.